Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Seres Therapeutics, Inc. (MCRB)

Seres posts $4.6 million Q2 net income on $25 million VOWST gain

Mixed Impact 3 of 5 earnings Written later

Seres reported second quarter 2026 net income of $4.6 million, compared with a net loss of $19.9 million a year earlier, driven by a $25 million gain from the Nestlé milestone termination payment. The company had $15.6 million in cash at June 30, 2026, and expects to fund operations through the first quarter of 2027, excluding any future partnership or financing proceeds.

Key points

  • Q2 2026 net income $4.6 million vs. net loss $19.9 million in Q2 2025; difference mainly the $25 million VOWST gain
  • Research and development expenses $9.1 million (vs. $12.9 million) and G&A $7.1 million (vs. $10.3 million)
  • $5.8 million impairment charge tied to early termination of part of the 101 Cambridgepark Drive lease
  • Cash of $15.6 million at June 30, 2026; runway through Q1 2027 assumes the $12.5 million Nestlé payment due October 1, 2026

The filing

CompanySeres Therapeutics, Inc. (MCRB)
Form8-K, current report
Filed with the SECAug 5, 2026, 7:05 AM ET
Accession number0001193125-26-333820

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.